Cao Zhiyong, Chen Zhenhua, Yang Jiawei, Shen Xiaozhu, Chen Chen, Zhu Xiangyang, Fang Qi
Department of Neurology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People's Republic of China.
Department of Neurology, The Second Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, People's Republic of China.
Int J Gen Med. 2024 Dec 11;17:6029-6035. doi: 10.2147/IJGM.S491039. eCollection 2024.
Elevated serum pentraxin-3 levels are generally considered a risk factor for atherosclerosis. However, there is limited data on the relationship between pentraxin-3 and cerebral infarction (CI) accompanied by intracranial atherosclerotic stenosis (ICAS). This study aims to investigate the association between pentraxin-3 (PTX-3) and short-term recurrence in cerebral infarction caused by ICAS patients within one year.
A prospective observational study was conducted. Cerebral infarction accompanied by intracranial atherosclerotic stenosis (CI-ICAS) patients were selected from January 2020 to December 2023. Recurrent ischemic stroke (RIS) is defined as a new neurological deficit that appears after a period of clinical stabilization, lasting more than 24 hours, with an attributable new ischemic lesion that can be confirmed by CT or MRI. Serum pentraxin-3 levels were determined on admission. Multivariate logistic regression analysis was used to investigate the relationship between serum pentraxin-3 and RIS.
Among 398 patients enrolled, 112 cases (28.1%) had recurrence within one year. The elevation of serum PTX-3 level in patients accompanied with ICAS was independently correlated with recurrent stroke. Therefore, it is worth considering the possibility of intervening in higher PTX-3 levels. Serum pentraxin-3 was significantly higher in patients with RIS (15.16 vs 10.21 µmol/L, <0.001). Correlation analysis showed that PTX-3 was correlated with age, LDL, Hs-CRP, Baseline NIHSS score, and Hcy ( < 0.001). Univariate logistic regression analysis showed that pentraxin-3 remained an independent predictor of recurrent ischemic stroke after adjusting for major confounding factors (OR = 1.21, 95% CI: 1.06-1.39, = 0.007).
The elevation of serum pentraxin-3 level in patients with ischemic stroke was independently correlated with the recurrence of stroke within one year. Therefore, intervention in serum pentraxin-3 levels may be worth considering.
血清五聚体-3水平升高通常被认为是动脉粥样硬化的危险因素。然而，关于五聚体-3与伴有颅内动脉粥样硬化狭窄（ICAS）的脑梗死（CI）之间关系的数据有限。本研究旨在探讨五聚体-3（PTX-3）与ICAS患者一年内脑梗死短期复发之间的关联。
进行一项前瞻性观察性研究。选取2020年1月至2023年12月期间伴有颅内动脉粥样硬化狭窄的脑梗死（CI-ICAS）患者。复发性缺血性卒中（RIS）定义为在一段临床稳定期后出现的新的神经功能缺损，持续超过24小时，伴有可通过CT或MRI确认的归因于新的缺血性病变。入院时测定血清五聚体-3水平。采用多因素logistic回归分析探讨血清五聚体-3与RIS之间的关系。
在纳入的398例患者中，112例（28.1%）在一年内复发。伴有ICAS的患者血清PTX-3水平升高与复发性卒中独立相关。因此，值得考虑干预较高PTX-3水平的可能性。RIS患者的血清五聚体-3显著更高（15.16对10.21µmol/L，<0.001）。相关性分析显示PTX-3与年龄、低密度脂蛋白、超敏C反应蛋白、基线美国国立卫生研究院卒中量表评分和同型半胱氨酸相关（<0.001）。单因素logistic回归分析显示，在调整主要混杂因素后，五聚体-3仍然是复发性缺血性卒中的独立预测因子（比值比=1.21，95%置信区间：1.06-1.39，P=0.007）。
缺血性卒中患者血清五聚体-3水平升高与一年内卒中复发独立相关。因此，值得考虑干预血清五聚体-3水平。
